{
  "docId": "019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "docSlug": "6ded4b1cfe2c",
  "documentTitle": "Bristol-Myers Squibb Company (BMY)",
  "authorId": "03_Starboard_Value",
  "authorName": "Starboard Value",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2019-03-18 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 109,
  "pageCount": 197,
  "prevPage": 108,
  "nextPage": 110,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a 'CEO quote contradiction' or 'authority citation' approach by leveraging Arena's own presentation materials to build the activist's case.",
  "elementsJson": [
    "headline_text",
    "subtitle_text",
    "screenshot",
    "quote_block"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6d9-fc4318e06f9b/109",
  "deckHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b#slide-109",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Arena Pharmaceuticals may be coming to market with a product that is superior to ozanimod",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0f19-73dd-8e9b-57c28f13ffc3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "image",
      "text": "Arena Pharmaceuticals Company Presentation charts",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55e097aa-a254-4d95-9b9a-be7e34b45b9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "Arena Pharmaceuticals is also developing a S1P receptor modulator – the same mechanism of action as ozanimod – that the company believes outcompetes ozanimod across a number of factors.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a03b6aac-3e5d-46de-b8e5-476f4112fc44",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.44,
        "x": 0.52,
        "y": 0.45
      },
      "kind": "quote",
      "text": "We have very quick onset of action. We lower lymphocytes 3x faster than ozanimod.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "271cc3c9-b54d-4979-a75c-1426c59b61e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.44,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "quote",
      "text": "Importantly, physicians are moving more and more to oral therapies... they routinely select etrasimod over ozanimod.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43d9c1cc-73f2-4648-8f41-06cc79ee8359",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.44,
        "x": 0.52,
        "y": 0.65
      },
      "kind": "quote",
      "text": "We also have an extremely fast offset of action... we actually don't know how long it takes to get ozanimod [out] because that data has never been presented.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8cc4df08-cf95-4090-aa10-d9a949c36f0e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"Importantly, physicians are moving more and more to oral therapies, are looking more and more to oral therapies. And in those oral therapies, routinely, physicians select S1P modulators over JAK inhibitors. And when we put blinded profiles in front of physicians, they routinely select etrasimod over ozanimod.\" — Amit Munshi, CEO & President of Arena Pharma, January 2019",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-0f19-73dd-8e9b-585e83df9b7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "title",
      "text": "Arena Pharmaceuticals may be coming to market with a product that is superior to ozanimod",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ad95a19-3e8c-4c1a-a3a8-485808252fcd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "Arena Pharmaceuticals Has a Competing Product That May Be Superior Across a Number of Factors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a8d2db2-fee7-4242-a167-739324a0fca3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority_citation",
      "slug": null,
      "matchId": "1f41bd85-2f0b-4a63-b3d6-0e4eac8cf4ae",
      "evidence": "Uses CEO quotes from the target company to validate the activist's thesis.",
      "confidence": 0.95
    },
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "573aba0f-9bdb-4706-bb5e-063d1e6721a8",
      "evidence": "Direct side-by-side comparison of clinical data and physician preference metrics.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}